Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

Inclusion criteria

• Patients with type 2 diabetes who have never received any hypoglycemic treatment；
• Fasting plasma glucose (FPG) between 7.0 mmol/l (126 mg/dl) and 16.7 mmol/l (300 mg/dl);
• glycosylated hemoglobin A1C≥8.5%;
• Aged between 20 and 70 years 5） body mass index (BMI) 22-35 kg/m2.

Exclusion criteria

• Type 1 diabetes or special type of diabetes;
• Acute complications of diabetes (including DKA, HHS and lactic acidosis)
• Serious microvascular complications: proliferative stage of retinopathy; urine AER >300 mg/g or urine protein positive, quantification >0.5 g/d; uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy;
• Severe macrovascular complications: acute cerebrovascular accident, acute coronary syndrome, vascular intervention for peripheral arterial disease or amputation requiring hospitalization within 12 months prior to enrollment;
• Persistently increased blood pressure >180/110 mmHg;
• Blood creatinine clearance less than 50 ml/min, alanine aminotransferase ≥2.5×upper limit of normal, total bilirubin ≥1.5×upper limit of normal;
• Hemoglobin <100 g/L or need regular blood transfusion;
• Use of drugs that may influence blood glucose within 12 weeks;
• Systemic infection or serious concomitant disease; patients with malignancy or chronic diarrhea;
• Uncontrolled endocrine gland dysfunction;
• Patients with mental or communication disorders;
• Chronic cardiac insufficiency, heart function class III and above;
• Pregnant women, lactating women and women of child bearing age who are not willing to take contraception during the study;
• Subjects who don't cooperate, cannot be followed up or have difficulty in completing the study considered by the investigator.